Generate Biomedicines and Zealand Pharma ink AI protein deal
Generate Biomedicines and Zealand Pharma have signed a collaboration and licence agreement to develop multispecific protein therapeutics for obesity and other metabolic diseases, with Generate eligible to receive up to nearly $1.2 billion in milestone payments across two initial programmes.
Under the deal terms, Generate will deploy its generative AI platform to lead research through to lead-candidate selection. Zealand Pharma will then take responsibility for clinical development, regulatory submissions, and global commercialisation. Generate receives $30 million upfront, up to $35 million in early preclinical milestones, and tiered royalties on future net sales. The agreement also includes an option for a third programme.
The deal
The collaboration is structured to exploit complementary strengths. Zealand Pharma brings more than 25 years of peptide research and development experience, two marketed products, and a proprietary metabolic-disease data platform. Generate contributes its computational design capability, which integrates large-language-model-style generative AI with high-throughput wet-lab experimental validation to engineer protein candidates with defined biological functions.
Utpal Singh, chief scientific officer at Zealand Pharma, said the partnership "expands our toolbox to include proteins, complementing our existing small-molecule and peptide capabilities and opening new approaches for polypharmacology." Generate chief executive Mike Nally framed the collaboration around first defining the target product profile for each programme, then using the platform to design candidates that meet or exceed it.
The agreement is notable for the modality breadth it adds to Zealand Pharma's pipeline. The Copenhagen-based company has built a strong position in GLP-1 and peptide-based treatments, a segment that has attracted intense investment and deal activity since the commercial success of semaglutide. Moving into AI-designed multispecific proteins gives Zealand access to mechanisms that peptide chemistry alone cannot easily reach, including simultaneous engagement of multiple receptor targets implicated in cardiometabolic disease.
Market context
The obesity and metabolic disease space has become one of the most competitive in biopharmaceuticals, with Novo Nordisk, Eli Lilly, and a growing cohort of clinical-stage biotechs pursuing incremental and next-generation mechanisms. AI-driven protein design is an emerging differentiator in this environment: a number of well-funded companies, including Absci and Profluent among others, are applying generative models to antibody and protein engineering, though multispecific protein design for metabolic targets remains a relatively early frontier.
For Generate, the Zealand deal extends The Generate Platform beyond its initial oncology and immunology focus, validating the technology in a therapeutic area with substantial commercial precedent. The company listed on NASDAQ and is advancing its own internal pipeline in parallel, making this a financially meaningful non-dilutive transaction at a stage when preclinical biotechs face tighter capital markets.
Near-term milestones to watch include the nomination of lead candidates from the first two programmes and any data readouts that would support IND filings under Zealand Pharma's stewardship. Both companies will be keen to demonstrate that generative AI can materially compress the timeline from target to clinical candidate in one of pharma's most watched therapeutic areas.